Literature DB >> 33284680

Peripheral Neuropathy and All-Cause and Cardiovascular Mortality in U.S. Adults : A Prospective Cohort Study.

Caitlin W Hicks1, Dan Wang2, Kunihiro Matsushita2, B Gwen Windham3, Elizabeth Selvin2.   

Abstract

BACKGROUND: Growing evidence indicates that peripheral neuropathy (PN) is common even in the absence of diabetes. However, the clinical sequelae of PN have not been quantified in the general population.
OBJECTIVE: To assess the associations of PN with all-cause and cardiovascular mortality in the general adult population of the United States.
DESIGN: Prospective cohort study.
SETTING: NHANES (National Health and Nutrition Examination Survey), 1999 to 2004. PARTICIPANTS: 7116 adults aged 40 years or older who had standardized monofilament testing for PN. MEASUREMENTS: Cox regression to evaluate the associations of PN with all-cause and cardiovascular mortality after adjustment for demographic and cardiovascular risk factors, overall and stratified by diabetes status.
RESULTS: The overall prevalence of PNSE) was 13.5% ± 0.5% (27.0% ± 1.4% in adults with diabetes and 11.6% ± 0.5% in adults without diabetes). During a median follow-up of 13 years, 2128 participants died, including 488 of cardiovascular causes. Incidence rates (per 1000 person-years) of all-cause mortality were 57.6 (95% CI, 48.4 to 68.7) in adults with diabetes and PN, 34.3 (CI, 30.3 to 38.8) in adults with PN but no diabetes, 27.1 (CI, 23.4 to 31.5) in adults with diabetes but no PN, and 13.0 (CI, 12.1 to 14.0) in adults with no diabetes and no PN. In adjusted models, PN was significantly associated with all-cause mortality (hazard ratio [HR], 1.49 [CI, 1.15 to 1.94]) and cardiovascular mortality (HR, 1.66 [CI, 1.07 to 2.57]) in participants with diabetes. In those without diabetes, PN was significantly associated with all-cause mortality (HR, 1.31 [CI, 1.15 to 1.50]), but the association between PN and cardiovascular mortality was not statistically significant after adjustment (HR, 1.27 [CI, 0.98 to 1.66]). LIMITATION: Prevalent cardiovascular disease was self-reported, and PN was defined by monofilament testing only.
CONCLUSION: Peripheral neuropathy was common and was independently associated with mortality in the U.S. population, even in the absence of diabetes. These findings suggest that decreased sensation in the foot may be an underrecognized risk factor for death in the general population. PRIMARY FUNDING SOURCE: National Institute of Diabetes and Digestive and Kidney Diseases and National Heart, Lung, and Blood Institute of the National Institutes of Health.

Entities:  

Mesh:

Year:  2020        PMID: 33284680      PMCID: PMC7932559          DOI: 10.7326/M20-1340

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  37 in total

Review 1.  Epidemiology of foot ulceration and amputation: can global variation be explained?

Authors:  David J Margolis; William Jeffcoate
Journal:  Med Clin North Am       Date:  2013-04-25       Impact factor: 5.456

2.  Prevalence of lower extremity diseases associated with normal glucose levels, impaired fasting glucose, and diabetes among U.S. adults aged 40 or older.

Authors:  Edward W Gregg; Qiuping Gu; Desmond Williams; Nathalie de Rekeneire; Yiling J Cheng; Linda Geiss; Michael Engelgau
Journal:  Diabetes Res Clin Pract       Date:  2007-02-15       Impact factor: 5.602

3.  Sensory neuropathy in non-insulin-dependent diabetes mellitus. The San Luis Valley Diabetes Study.

Authors:  G M Franklin; L B Kahn; J Baxter; J A Marshall; R F Hamman
Journal:  Am J Epidemiol       Date:  1990-04       Impact factor: 4.897

Review 4.  11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2019.

Authors: 
Journal:  Diabetes Care       Date:  2019-01       Impact factor: 19.112

5.  Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications.

Authors:  Elisa Dal Canto; Antonio Ceriello; Lars Rydén; Marc Ferrini; Tina B Hansen; Oliver Schnell; Eberhard Standl; Joline Wj Beulens
Journal:  Eur J Prev Cardiol       Date:  2019-11-13       Impact factor: 7.804

6.  Risk factors for mortality in Type II (non-insulin-dependent) diabetes: evidence of a role for neuropathy and a protective effect of HLA-DR4.

Authors:  C M Forsblom; T Sane; P H Groop; K J Tötterman; M Kallio; C Saloranta; L Laasonen; P Summanen; M Lepäntalo; L Laatikainen; E Matikainen; A M Teppo; S Koskimies; L Groop
Journal:  Diabetologia       Date:  1998-11       Impact factor: 10.122

7.  Idiopathic neuropathy patients are at high risk for metabolic syndrome.

Authors:  A Gordon Smith; Kristi Rose; J Robinson Singleton
Journal:  J Neurol Sci       Date:  2008-07-07       Impact factor: 3.181

Review 8.  The metabolic syndrome and neuropathy: therapeutic challenges and opportunities.

Authors:  Brian Callaghan; Eva Feldman
Journal:  Ann Neurol       Date:  2013-09       Impact factor: 10.422

9.  The significant effect of diabetes duration on coronary heart disease mortality: the Framingham Heart Study.

Authors:  Caroline S Fox; Lisa Sullivan; Ralph B D'Agostino; Peter W F Wilson
Journal:  Diabetes Care       Date:  2004-03       Impact factor: 19.112

Review 10.  Recent advances in understanding chemotherapy-induced peripheral neuropathy.

Authors:  Richard Gordon-Williams; Paul Farquhar-Smith
Journal:  F1000Res       Date:  2020-03-11
View more
  6 in total

Review 1.  Current and Emerging Pharmacotherapeutic Interventions for the Treatment of Peripheral Nerve Disorders.

Authors:  Jeremy Chung Bo Chiang; Ria Arnold; Roshan Dhanapalaratnam; Maria Markoulli; Arun V Krishnan
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-15

2.  Glycated albumin and HbA1c as markers of lower extremity disease inUS adults with and without diabetes.

Authors:  Caitlin W Hicks; Dan Wang; Kunihiro Matsushita; John W McEvoy; Robert Christenson; Elizabeth Selvin
Journal:  Diabetes Res Clin Pract       Date:  2022-01-20       Impact factor: 5.602

Review 3.  Cardiac autonomic neuropathy and risk of cardiovascular disease and mortality in type 1 and type 2 diabetes: a meta-analysis.

Authors:  Mahin Chowdhury; Sarah Nevitt; Aikaterini Eleftheriadou; Prathap Kanagala; Hani Esa; Daniel J Cuthbertson; Abd Tahrani; Uazman Alam
Journal:  BMJ Open Diabetes Res Care       Date:  2021-12

Review 4.  Flavonoids Alleviate Peripheral Neuropathy Induced by Anticancer Drugs.

Authors:  Manaal Siddiqui; Basma Abdellatif; Kevin Zhai; Alena Liskova; Peter Kubatka; Dietrich Büsselberg
Journal:  Cancers (Basel)       Date:  2021-03-29       Impact factor: 6.639

5.  Association of Cardiovascular Autonomic Neuropathy and Distal Symmetric Polyneuropathy with All-Cause Mortality: A Retrospective Cohort Study.

Authors:  Orsolya E Vági; Márk M Svébis; Beatrix A Domján; Anna E Körei; Ildikó Istenes; Zsuzsanna Putz; Szilvia Mészáros; Noémi Hajdú; Magdolna Békeffy; Solomon Tesfaye; Péter Kempler; Viktor J Horváth; Adam G Tabák
Journal:  J Diabetes Res       Date:  2021-05-28       Impact factor: 4.011

6.  Prevalence of peripheral neuropathy defined by monofilament insensitivity in middle-aged and older adults in two US cohorts.

Authors:  Caitlin W Hicks; Dan Wang; B Gwen Windham; Kunihiro Matsushita; Elizabeth Selvin
Journal:  Sci Rep       Date:  2021-09-27       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.